Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;26(4):466-70.
doi: 10.3978/j.issn.1000-9604.2014.08.09.

Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)

Lian Chen  1 , Rui Chen  1 , Zhe Zhu  1 , Yichen Zhang  1 , Zhengwei Wen  1 , Yun Li  1 , Xiaoming Li  1 , Yuwen Luo  1 , Liyu Ma  1 , Shuguang Lin  1 , Xin Chen  1
Affiliations

Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)

Lian Chen et al. Chin J Cancer Res. 2014 Aug.

Abstract

Purpose: A number of different clinical characteristics have been reported to singly correlate with therapeutic activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced non-small-cell lung cancer (NSCLC). This study aimed to identify predictive factors associated with prognostic benefits of gefitinib.

Patients and methods: EGFR gene typing in 33 advanced NSCLC patients received gefitinib (250 mg/day) were analyzed with mutant-enriched PCR assay. Gefitinib response was evaluated with potential predictive factors retrospectively.

Results: The overall objective response rate (ORR) and median progression-free survival (PFS) in the 33 patients treated by gefitinib were 45.5% and 3.0 (2.0-4.0) months. The ORR and median PFS in EGFR gene mutation patients were significantly higher/longer than those in EGFR gene wild-type patients (P<0.01). Similarly, the ORR and median PFS in non-smoker patients were significantly higher/longer than those in smoker patients (P<0.05, P<0.01, respectively). However, no difference for ORR and median PFS occurred between male and female patients. Logistic multivariate analysis showed that only EGFR mutated gene was significantly associated with the ORR (P<0.01). Both EGFR mutated gene and non-smoker were the major factors that contributed to PFS (P<0.05).

Conclusions: EGFR mutated gene and non-smoker status are potential predictors for gefitinib response in NSCLC patients.

Keywords: Epidermal growth factor receptor inhibitor (EGFR inhibitor); gefitinib; gender; gene mutation; non-small-cell lung cancer (NSCLC); smoking.

PubMed Disclaimer

References

    1. Sequist LV, Joshi VA, Jänne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90-8 - PubMed
    1. Landi L, Cappuzzo F.Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res 2013;2:40-9 - PMC - PubMed
    1. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37 - PubMed
    1. Song Z, Yu X, He C, et al. Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. J Thorac Dis 2013;5:400-5 - PMC - PubMed
    1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46 - PubMed